Therapy Areas: Autoimmune
MiNA Therapeutics Names Clement-Davies, Lechler as Independent Directors
23 December 2021 - - UK-based RNA therapeutics company MiNA Therapeutics Ltd has expanded its board with the appointment of Susan Clement-Davies and Professor Sir Robert Lechler as independent directors, effective 1 January 2022, the company said.

Clement-Davies is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including as managing director of Equity Capital Markets at Citigroup Global Markets Ltd. and managing director at Torreya Partners LLC.

She is currently a non-executive director of Scancell Holdings, a UK listed biotechnology company developing innovative immunotherapies, EvgenPharma plc, a UK-listed clinical stage drug development company, and Exploristics, a world-provider of biosimulation software and biostatistics services for clinical trials.

Clement-Davies is also Corporate Finance Advisor for Theolytics, a biotechnology company developing anticancer viral therapies, and an Advisor for Oxford Sciences Innovation, the world's largest university-partnered venture firm.

In addition, she is a member of the Innovation Advisory Group for the Chelsea and Westminster Hospital NHS Foundation Trust.

Lechler is a recognised leader in biomedical research, management and governance with over 40 years of distinguished experience in academic medicine, having started his immunology career in 1979.

Since then, Lechler has held various leadership roles in a range of hospitals and laboratories, including serving as Head of Imperial College London's Division of Medicine, vice Principal (Health) of King's College School, and Executive director of King's Health Partners Academic Health Sciences Centre.

He has also been at the forefront of scientific innovation, nationally, through his Presidency of the Academy of Medical Sciences, Membership of the UK Council for Science and Technology, and chairmanship of the UK MHRA Clinical Trials Expert Advisory Group.

In 2012, Lechler was Knighted in the Queen's Birthday Honours for his services to academic medicine, which has centred around immunology, cancer and transplantation.

He is currently a non-executive director of Quell Therapeutics, a biopharmaceutical company specialising in addressing a range of autoimmune and inflammatory diseases through cell therapy.

MiNA Therapeutics is a leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a revolutionary new class of medicines that can restore or boost normal function in patients' cells.


Related Headlines